上QQ阅读APP看书，第一时间看更新
1.3 预后
预后分组参考Gökbuget等 ［5］发表的危险度分组标准（表1-1）。细胞遗传学分组参考NCCN 2019（表1-2）。
ALL诊断确立后，应根据具体分型、预后分组采用规范化的分层治疗策略，以取得最佳治疗效果。
表1-1 成人ALL预后分组
表1-1 成人ALL预后分组（续表）
注：CR.完全缓解；MRD.微小残留病；？.可能有意义，但尚未达成共识
表1-2 NCCN2019年B-ALL细胞遗传学危险度分组
参考文献
［1］ DE HAAS V, ISMAILA N, ADVANI A, et al. Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. J Clin Oncol, 2019 Jan 20, 37 (3): 239-253.
［2］ NCCN Clinical Practice Guidelines in Oncology-Acute Lymphoblastic Leukemia (2019 Version 2) [DB/OL]. http: //www. nccn. org.
［3］ BENE MC, CASTOLDI G, KNAPP W, et al. Proposals for the immunological classi fi cation of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia, 1995, 9 (10): 1783-1786.
［4］ ARBER DA, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia. Blood, 2016, 127: 2391-2405.
［5］ GÖKBUGET N, HOELZER D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol, 2009, 46 (1): 64-75.